Log in

Relevant bibliographies by topics / Parenteral drug delivery

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Parenteral drug delivery'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Parenteral drug delivery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Parenteral drug delivery"

1

Gulati, Neha, and Himanshu Gupta. "Parenteral Drug Delivery: A Review." Recent Patents on Drug Delivery & Formulation 5, no. 2 (May 1, 2011): 133–45. http://dx.doi.org/10.2174/187221111795471391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Collins-Gold, L. C., R. T. Lyons, and L. C. Bartholow. "Parenteral emulsions for drug delivery." Advanced Drug Delivery Reviews 5, no. 3 (September 1990): 189–208. http://dx.doi.org/10.1016/0169-409x(90)90016-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kwatra, Shubhika, Guncha Taneja, and Nimisha Nasa. "Alternative Routes of Drug Administration- Transdermal, Pulmonary & Parenteral." Indo Global Journal of Pharmaceutical Sciences 02, no. 04 (2012): 409–26. http://dx.doi.org/10.35652/igjps.2012.47.

Full text

Abstract:

Oral Route is considered to be the most common route of drug delivery to obtain a systemic effect. However, with the recent developments in the field of drug delivery, it has been found that delivery through alternative routes is sometimes more beneficial. This article deals with the salient features, advantages and disadvantages of some of the alternative routes of drug administration- Transdermal, Pulmonary and Parenteral routes. Though the mechanisms of action of drugs delivered by these routes are different, they offer a common advantage- increased Therapeutic Index with simultaneously decreased side effects. The latest innovations in drug formulations delivered through these routes have also been discussed. © 2011 IGJPS. All rights reserved.

APA, Harvard, Vancouver, ISO, and other styles

4

Chaubal, Mahesh V., and Theodore J. Roseman. "Drug delivery trends for parenteral therapeutics." Drug Delivery System 21, no. 4 (2006): 388–97. http://dx.doi.org/10.2745/dds.21.388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Neupane, Rabin, Sai H. S. Boddu, Mariam Sami Abou-Dahech, Rinda Devi Bachu, David Terrero, R. Jayachandra Babu, and Amit K. Tiwari. "Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities." Pharmaceutics 13, no. 7 (June 26, 2021): 960. http://dx.doi.org/10.3390/pharmaceutics13070960.

Full text

Abstract:

Chemotherapeutic drugs are primarily administered to cancer patients via oral or parenteral routes. The use of transdermal drug delivery could potentially be a better alternative to decrease the dose frequency and severity of adverse or toxic effects associated with oral or parenteral administration of chemotherapeutic drugs. The transdermal delivery of drugs has shown to be advantageous for the treatment of highly localized tumors in certain types of breast and skin cancers. In addition, the transdermal route can be used to deliver low-dose chemotherapeutics in a sustained manner. The transdermal route can also be utilized for vaccine design in cancer management, for example, vaccines against cervical cancer. However, the design of transdermal formulations may be challenging in terms of the conjugation chemistry of the molecules and the sustained and reproducible delivery of therapeutically efficacious doses. In this review, we discuss the nano-carrier systems, such as nanoparticles, liposomes, etc., used in recent literature to deliver chemotherapeutic agents. The advantages of transdermal route over oral and parenteral routes for popular chemotherapeutic drugs are summarized. Furthermore, we also discuss a possible in silico approach, Formulating for Efficacy™, to design transdermal formulations that would probably be economical, robust, and more efficacious.

APA, Harvard, Vancouver, ISO, and other styles

6

Bulić, Matea, and Catherine Tuleu. "Rectal Drug Delivery to Paediatric Population." Hrvatski časopis zdravstvenih znanosti 1, no. 2 (November 29, 2021): 76–80. http://dx.doi.org/10.48188/hczz.1.2.5.

Full text

Abstract:

Despite its unpopularity, the rectal route of paediatric drug administration remains of interest especially in pre-school children as it can overcome some drug delivery challenges with oral and parenteral routes. Few studies have been conducted on the use and acceptability of traditional rectal dosage forms (i.e., suppositories, enemas and gels) in different parts of the world. It showed that barrier to adoption could be linked with poor knowledge, little information and understanding of this administration modality. Reformulation for the rectal delivery of drugs intended for oral and/or parenteral administration that do not reach their full potential, was explored by a study at University College London. The top 3 candidates were Azithromycin, Amodiaquine and Raltegravir. Little rectal delivery innovation has occurred but topics such as acceptability and use of rectal drug delivery; types of rectal dosage forms and reformulation considerations are discussed presently in order to raise awareness around the need to modernise rectal dosage forms this to achieve the full potential for successful reformulation.

APA, Harvard, Vancouver, ISO, and other styles

7

Haranath, Chinthaginjala. "Recent advances in lipid based nanovesicles for transdermal drug delivery." Journal of medical pharmaceutical and allied sciences 11, no. 6 (December 31, 2022): 5375–81. http://dx.doi.org/10.55522/jmpas.v11i6.4273.

Full text

Abstract:

Lipid based nanovesicles are the formulations which are used for the delivery of hydrophilic, hydrophobic and amphiphilic drugs or compounds. They are very helpful for the drugs which are hydrophilic and irritant drugs that can be encapsulated and delivered to the target site. They are very advantageous over conventional formulations. Lipid based nanovesicular systems will efficaciously help the drugs addressing the issues of solubility and penetration thereby promotes bioavailability. Now a days lipid based nanovesicles for transdermal delivery of drug has become very useful especially for hydrophilic drugs. The use of the nanovesicles for transdermal drug delivery will overcome the drawbacks associated with the route of drug delivery, such as oral and parenteral. Lipid based nanocarriers includes liposomes, transferosomes, ethosomes, niosomes, ufasomes, spinghosomes, pharmacosomes etc., This review article describes the types, formulation methods, evaluation and the research works done on lipid based nanovesicles for transdermal delivery of the drug.

APA, Harvard, Vancouver, ISO, and other styles

8

Chavda, Vivek P., Shilpa Dawre, Anjali Pandya, Lalitkumar K. Vora, Dharti H. Modh, Vidhi Shah, Divyang J. Dave, and Vandana Patravale. "Lyotropic liquid crystals for parenteral drug delivery." Journal of Controlled Release 349 (September 2022): 533–49. http://dx.doi.org/10.1016/j.jconrel.2022.06.062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wissing, S. A., O. Kayser, and R. H. Müller. "Solid lipid nanoparticles for parenteral drug delivery." Advanced Drug Delivery Reviews 56, no. 9 (May 2004): 1257–72. http://dx.doi.org/10.1016/j.addr.2003.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Anureet Arora, Manju Nagpal, and Geeta Aggarwal. "Microneedle Mediated Vaccine Delivery: A Comprehensive Review." Journal of Pharmaceutical Technology, Research and Management 5, no. 2 (November 2, 2017): 163–84. http://dx.doi.org/10.15415/jptrm.2017.52011.

Full text

Abstract:

Microneedles can be representative for paradigm shift of drug delivery from patient non-compliant parenteral injections to patient compliant drug delivery system, which can be utilized for administration of vaccines particularly along with macromolecular/micromolecular drugs. The concept of microneedles came into existence many decades ago but the use of microneedles to achieve efficient delivery of drugs into the skin became subject of research from mid of 1990’s. Various types of microneedles were utilized to enhance delivery of drugs and vaccines including solid microneedles for pre-treatment of skin to enhance drug permeability, dissolvable polymeric microneedles encapsulating drugs, microneedles coated with drugs and hollow microneedles for infusion of drugs through the skin. Microneedles have shown promisingdelivery of vaccines through skin in literature. But the successful utilization of this system for vaccine drug delivery mainly depends on design of device to facilitate microneedle infusion, vaccine stability and storage in system, recovery of skin on removal of microneedle and improved patient compliance. This article reviews the conventional and advanced methods of vaccine drug deliver, microneedles for drug delivery, types of microneedles, advantages of microneedles and potential of microneedles for vaccine drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Parenteral drug delivery"

1

Jørgensen, Lene. "Lipid based drug delivery systems for parenteral delivery of proteins /." Cph. : Department of Pharmaceutics, the Danish University of Pharmaceutical Sciences, 2004. http://www.dfh.dk/phd/defences/lenejoergensen.htm.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Nugent, Josephine. "Design and delivery of non-parenteral vaccines." Thesis, Queen's University Belfast, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.337026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Babu, Kavitha Mary Vadakkel. "The Development of a Novel Controlled Release Drug Delivery System." The University of Waikato, 2007. http://hdl.handle.net/10289/2590.

Full text

Abstract:

The aim of this research was to formulate, characterise and assess the feasibility of a novel drug delivery system known as the in situ gelling matrix (ISGM) where a hydrophilic polymer is suspended in a non-aqueous solvent that converts into a gel when injected subcutaneously or intramuscularly thus giving a controlled release matrix for a drug. Although the concept has been patented with claims that this kind of drug delivery is achievable in theory for a wide variety of candidate substances, actual formulation studies for making a commercially viable product for this technology are completely lacking in practice. The research embodied in this thesis addresses this lack. Initial studies involved conducting a biocompatibility study using the HET-CAM (hens egg test - chorioallantoic membrane) test on a range of possible ingredients for the delivery system. The materials deemed biocompatible were then carried through to a screening process where the physical stability of the hydrophilic polymers in non-aqueous solvents was monitored. It was found that the hydrophilic polymers tested sedimented rapidly in the non-aqueous solvents indicating such a system was not physically stable. Consequently, density-inducing or viscosity-inducing agents were added to the non-aqueous solvents to retard the sedimentation rate. The addition of polycarbophil, a viscosity-inducing agent, clearly increased the viscosity of the system. However, undesirable formation of polycarbophil globules occurred during the manufacturing process, which caused batch-to-batch variations in the viscosity of the continuous phase. Various manufacturing methods were tested before arriving at the optimum procedure to prevent globule formation using a high speed dispersion tool. A final physical sedimentation analysis of candidate continuous phases and hydrophilic polymers was conducted for determining the ideal combination of ingredients to use in the system. These investigations finally led to the adoption of an optimum mix of components consisting of 10% (w/w) hydroxypropyl methylcellulose (HPMC) (the hydrophilic polymer) suspended in a continuous phase of propylene glycol (the non-aqueous solvent) containing 0.67% (w/w) polycarbophil (the viscosity inducing agent). Using this mix of components, the in situ gelling matrix system was then subjected to various characterisation studies including infrared (IR), differential scanning calorimetry (DSC), ultraviolet-visible (UV-Vis) spectrophotometry and redispersion studies. The chemical stability of the hydrophilic polymer and the continuous phase (the non-aqueous solvent and polycarbophil) was monitored and were found to be chemically stable over a 9 month period. The feasibility of the in situ gelling matrix technology as a controlled release device was assessed using the drug propranolol. In vitro drug release studies were conducted using a custom-built dissolution apparatus. The effect of various parameters such as the concentration of the hydrophilic gelling agent on the drug release rate was investigated. Increasing the concentration of the gelling agent in the formulation resulted in a slower rate of release. The drug release data were modelled using the Higuchi relationship and a power law relationship to compare the effects of the various parameters on the release rate Stability studies on the drug in the in situ gelling matrix system were carried out by storing samples in accelerated ageing conditions of 40 C / 75% relative humidity for 4 weeks. During this time, the samples were analysed each week by high performance liquid chromatography (HPLC). These demonstrated that no apparent drug degradation had occurred over the 4-week period. This indicates that the drug propranolol in the in situ gelling matrix system is stable under ambient conditions for at least 4 weeks. The results of this study demonstrated that the in situ gelling matrix technology is potentially viable as a drug delivery system and provide a practical methodology for the commercial development of such systems.

APA, Harvard, Vancouver, ISO, and other styles

4

Lance, Martin Richard. "Formulation and evaluation of novel amphotericin B oil/water triglyceride emulsions." Thesis, University of Nottingham, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Krenzlin, Stefanie [Verfasser]. "Challenging controlled drug delivery : matrix systems for oral and parenteral application / Stefanie Krenzlin." Berlin : Freie Universität Berlin, 2012. http://d-nb.info/1027816118/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Besslich, Lisa [Verfasser]. "Formulation and process development of biodegradable microparticles for controlled parenteral drug delivery / Lisa Beßlich." Berlin : Freie Universität Berlin, 2020. http://d-nb.info/1215572115/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Beßlich, Lisa [Verfasser]. "Formulation and process development of biodegradable microparticles for controlled parenteral drug delivery / Lisa Beßlich." Berlin : Freie Universität Berlin, 2020. http://d-nb.info/1215572115/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Meynell, Helen Mary. "Bacterial modulation of particle transport across the follicle-associated epithelium of Peyer's patches." Thesis, University of Nottingham, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.285656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gomes, Rodrigues Alexandre [Verfasser]. "Parenteral controlled drug delivery by novel direct injectable polymer (DIPO) : in situ forming implant / Alexandre Gomes Rodrigues." Halle, 2018. http://d-nb.info/1160514518/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

MAGRI, GIULIA. "DEVELOPMENT OF NOVEL BIODEGRADABLE MATERIALS STABLE TO STERILIZATION FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS." Doctoral thesis, Università degli Studi di Milano, 2019. http://hdl.handle.net/2434/607019.

Full text

Abstract:

Poly(lactide-co-glycolide) [PLGA] is the most exploited biodegradable and biocompatible material in the pharmaceutical field for the preparation of long- acting parenteral formulations, despite there are limitations related to the PLGA itself or to the final product to face with. These mainly include the limited ability in encapsulating hydrophilic compounds, the physical and chemical instabilities in aqueous media, the detrimental effect of the sterilization methods and the drop off in the micro-environmental pH upon degradation. Hence, there is the need to find new strategies for their overcoming. This doctoral thesis aimed to exploit the functionalization of PLGA backbone with anti-oxidants (g-AA-PLGA) and a novel biodegradable material, containing polyesters segments in a multi-block poly(urethane) organization, to address the main limitations related to PLGA, with emphasis on nano-particulate drug delivery systems. PLGA grafted to caffeic acid (g-CA-PLGA) nanoparticles (NP) showed an improved uptake in endothelial cells (EC) and smooth muscle cells (SMC), the representative cell populations in the artery wall. Thus, they were worth of interest for the loading of fluvastatin in restenosis prevention. The proliferation inhibition of human SMC was not significantly affected after the encapsulation of fluvastatin within g-CA-PLGA NP, with the effective concentration being 4 mcM compared to the 1 mcM of free fluvastatin, suggesting a control of the polymer on the drug release. A higher dose was necessary in the case of EC, indicating the possibility to inhibit SMC proliferation while the healing of the endothelium is on-going. All these aspects highlight the suitability of this system in the prevention of restenosis, after the local delivery with the angioplasty balloon (Chapter 1). However, during the development of the formulation, the selection and optimization of the drying process is required, also with the aim to coat the angioplasty balloon with eluting-NP. In this context, a preliminary study was performed and the obtained results revealed that maltodextrins (MDX), an excipient widely used in the pharmaceutical industry, can be also advantageously used as drying auxiliary agent. Indeed, they permit an easily reconstitution of NP dispersion in aqueous media, independently of the selected drying technique, namely spray-drying or freeze-drying. The performances of such excipient were demonstrated in the case of both PLGA and g-CA-PLGA NP (Chapter 2). The multi-block poly(ester-urethane) DegraPol® displays biocompatibility and biodegradability and consequently it is already used for the preparation of medical devices by electrospinning. Conversely, the possibility to design long-acting parenteral formulations is unknown as well as the possibility to conferee a spherical shape with the desired particle size and a narrow distribution. The performed work demonstrated that the emulsion/solvent evaporation method was the optimal process, with the possibility to cover size range from nano- to micro-meters. Nevertheless, the dispersant medium should be carefully studied, given the tendency of the particles to form aggregates due to the almost neutral Z-potential of the material (Chapter 3). All together the collected results, along with the known stability to sterilization process (ionizing radiations for g-AA-PLGA and ethylene oxide for DegraPol®), demonstrated that both PLGA grafted to anti-oxidant and DegraPol® are suitable materials for preparing particulate drug delivery systems that can overcome some of the limitations associated to PLGA. As a general consideration, it should be underlined that formulation development cannot be disconnected from the regulatory framework. Particularly for long-acting parenteral formulations, the elaboration of an appropriate in vitro test to study the release of the drug is critical, given the complexity in the set-up of methods able to efficiently discriminate products that can have different in vivo behaviour (Chapter 4). In the case of PLGA microspheres intended to sustain the release of a drug after the intra-articular administration, a bio-relevant approach was followed in the attempt to evaluate their performance under healthy and disease states simulated conditions. Formulation parameters such as PLGA lactide/glycolide ratio and the amount of drug encapsulated should be carefully considered to properly optimize the formulation. Furthermore, proteins contained in the release medium simulating the disease condition affected the release behaviour of microspheres. This suggests that simple buffers (i.e., PBS at physiological pH) cannot correctly figure out the conditions occurring in vivo after the administration, much less the pathological situation (Chapter 5).

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Parenteral drug delivery"

1

Dorati, Rossella. Copolymers in the preparation of parenteral drug delivery systems. Hauppauge, N.Y: Nova Science, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

D, Ensminger William, Selam Jean-Louis, and Drug Delivery System Symposium (1988 : Monaco, Monaco), eds. Update in drug delivery systems. Mount Kisco, N.Y: Futura Pub., 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wasan, Kishor M., ed. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2006. http://dx.doi.org/10.1002/0470097981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Peptide And Protein Drug Delivery (Advances in Parenteral Science). 2nd ed. Marcel Dekker Inc, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lee, Vincent. Peptide and Protein Drug Delivery (Advances in Parenteral Science, No 4). CRC, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wasan, Kishor M. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples. Wiley-Interscience, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wasan, Kishor M. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples. Wiley & Sons, Incorporated, John, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wasan, Kishor M. Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples. Wiley & Sons, Incorporated, John, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ludwig, John D., and Sandeep Nema. Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition. 3 Volume Set. Taylor & Francis Group, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Parenteral drug delivery"

1

Shahiwala, Aliasgar, Tejal A. Mehta, and Munira M. Momin. "Parenteral Drug Delivery Systems." In In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes, 283–318. Boca Raton : Taylor & Francis, 2018.: CRC Press, 2018. http://dx.doi.org/10.1201/b22448-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bontempo, John A. "Parenteral Formulation for Peptides, Proteins, and Monoclonal Antibodies Drugs: A Commercial Development Overview." In Drug Delivery, 321–39. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2005. http://dx.doi.org/10.1002/0471475734.ch15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bose, Sagarika. "Parenteral Drug Delivery for Older Patients." In Developing Drug Products in an Aging Society, 291–329. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43099-7_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Patel, Gayatri C. "Stimuli-Responsive Hydrogels for Parenteral Drug Delivery." In Functional Hydrogels in Drug Delivery, 234–58. Boca Raton, FL : CRC Press/ Taylor & Francis Group, 2017.: CRC Press, 2017. http://dx.doi.org/10.4324/9781315152271-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Patel, Gayatri. "Stimuli-Responsive Hydrogels for Parenteral Drug Delivery." In Functional Hydrogels in Drug Delivery, 234–58. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315152271-10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rehman, Nahid, and Anjana Pandey. "Nanoparticle Application in Non-Parenteral Applications." In Engineered Nanoparticles as Drug Delivery Systems, 67–78. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003252122-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Vhora, Imran, Denish Bardoliwala, Saketh Reddy Ranamalla, and Ankit Javia. "Parenteral Controlled and Prolonged Drug Delivery Systems: Therapeutic Needs and Formulation Strategies." In Novel Drug Delivery Technologies, 183–260. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3642-3_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Soo, Patrick Lim, Michael Dunne, Jubo Liu, and Christine Allen. "Nano-sized Advanced Delivery Systems as Parenteral Formulation Strategies for Hydrophobic Anti-cancer Drugs." In Nanotechnology in Drug Delivery, 349–83. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-77668-2_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lundholm, K. G., and A. Hyltander. "Long-Term and Home Parenteral Nutrition to Cancer Patients." In Drug Delivery in Cancer Treatment III, 41–51. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75938-3_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Wischke, C., and S. P. Schwendeman. "Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery." In Fundamentals and Applications of Controlled Release Drug Delivery, 171–228. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-0881-9_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Parenteral drug delivery"

1

McGee, James K., Koby Kubrin, Adeel Ahmed, and Michael G. Schrlau. "3D Printed Carbon Nanotube Array Interface for In Vivo Drug Delivery." In ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-71815.

Full text

Abstract:

The development of gene therapies, small molecules and nanoparticle-based therapeutics in pharmacology have prompted the need for parenteral administration as they possess limited bioactivity, low stability, high specificity and potency. The ability to directly deliver drugs to a specific area offers the capability of minimized required drug quantity, localization of exposure, and limited systemic side effects. Currently, there is no standard for the creation of implantable devices to monitor health status and provide therapeutic treatment. We explored the applications and uses for carbon nanotube based arrays for in vivo drug delivery, specifically as an implantable reusable mode of delivery. The increased availability of 3D printing allows for not only the rapid and reproducible fabrication of designs, but also the ability to incorporate these carbon nanotube arrays in ways that are not feasible using traditional machining methods. These techniques offer the means to design and fabricate a reservoir on carbon nanotube arrays to create a loadable reservoir that can regulate flow, dispensing cargo for mass cellular injection. This research focuses primarily on the development of an attachable drug reservoir for these devices and looks to explore the possibilities of designing reservoirs made out of biocompatible 3D printed materials such as plastics, alloys, or bioceramics. We explored several routes, including a rigid and semi-rigid, as well as how each design impacted the flow through the membrane.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!